Absci Corporation Overview
Pro stress-test →Absci is a synthetic biology company leveraging generative AI and scalable wet lab technologies to revolutionize the discovery and design of novel biologics through its Integrated Drug Creation™ platform, which seamlessly unifies biological drug discovery and cell line development. The company screens billions of cells per week and validates AI-designed antibodies in a matter of weeks.
Strategic Profile
Pro stress-test →Absci targets large pharmaceutical companies developing biologics and therapeutic proteins, as well as emerging and established biotechnology companies seeking advanced protein engineering solutions. The company's technology-forward strategy creates a scalable model applicable in human therapeutics and expanding into adjacent markets such as veterinary medicine.
Competitive Landscape
Pro stress-test →Absci competes in the AI-powered drug discovery and synthetic biology space against companies like Genentech/Roche, Moderna, Sesen Bio, and emerging AI biotech startups. Differentiation comes from integrated wet lab validation capabilities combined with generative AI, positioning it as a platform play rather than a single-asset company.
Industry Context
Absci Corporation operates in Synthetic Biology & AI-Powered Drug Discovery.
Key facts
Founded: 2011 · Headquarters: Vancouver, Washington · Employees: 194 · Revenue: $35M